发明名称 PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES
摘要 The present invention concerns a process by which a misfold in an Fc fusion molecule can be prevented or corrected. In one embodiment, the process comprises (a) preparing a pharmacologically active compound comprising an Fc domain; (b) treating the fusion molecule with a copper (II) halide; and (c) isolating the treated fusion molecule. The preferred copper (II) halide is CuCl2. The preferred concentration thereof is at least about 10 mM for fusion molecules prepared in E. coli; at least about 30 mM for fusion molecules prepared in CHO cells. Preferred pharmacologically active domains include OPG proteins, leptin proteins, soluble portions of TNF receptors (e.g., wherein the fusion molecule is etanercept), IL-1ra proteins, and TPO-mimetic peptides. The Fc domain preferably has a human sequence, with an Fc sequence derived from IgG1 most preferred.
申请公布号 WO0134638(A1) 申请公布日期 2001.05.17
申请号 WO2000US30798 申请日期 2000.11.10
申请人 AMGEN INC. 发明人 TREUHEIT, MICHAEL, J.;O'CONNER, SHEILA, R.;KOSKY, ANDREW, A.
分类号 C12N15/09;A61K38/00;A61K39/395;A61P3/04;A61P3/10;A61P19/10;A61P43/00;C07K1/113;C07K14/52;C07K14/705;C07K16/00;C07K19/00;C12P21/02;(IPC1-7):C07K1/113 主分类号 C12N15/09
代理机构 代理人
主权项
地址